Transformation Time For Minoryx With Leriglitazone Filing
EMA Submission For Rare Brain Disease Drug
The Spanish biotech, formed in 2011, is preparing for the potential European launch of leriglitazone for X-linked adrenoleukodystrophy after the EMA accepted its file.
You may also be interested in...
Bluebird bio will not see revenue for Zynteglo until it is infused into beta-thalassemia patients, which will take months due to the ex vivo gene therapy’s complex manufacturing and quality control process.
The Danish biotech is looking to end 2022 on a high after raising over $105m and posting positive Phase III data on glepaglutide.
The Swedish biotech is well positioned with soon-to-be late-stage clinical assets, commercial validation and a strong pipeline, new CEO Richard Godfrey tells Scrip.